Sphingosine 1-phosphate, a potential target in neovascular retinal disease

Simple item page
dc.contributor.authorAlshaikh, Rasha A.
dc.contributor.authorRyan, Katie B.
dc.contributor.authorWaeber, Christian
dc.contributor.funderIrish Research Councilen
dc.date.accessioned2021-05-26T10:35:33Z
dc.date.available2021-05-26T10:35:33Z
dc.date.issued2021-05-07
dc.date.updated2021-05-26T10:09:36Z
dc.description.abstractNeovascular ocular diseases (such as age-related macular degeneration, diabetic retinopathy and retinal vein occlusion) are characterised by common pathological processes that contribute to disease progression. These include angiogenesis, oedema, inflammation, cell death and fibrosis. Currently available therapies target the effects of vascular endothelial growth factor (VEGF), the main mediator of pathological angiogenesis. Unfortunately, VEGF blockers are expensive biological therapeutics that necessitate frequent intravitreal administration and are associated with multiple adverse effects. Thus, alternative treatment options associated with fewer side effects are required for disease management. This review introduces sphingosine 1-phosphate (S1P) as a potential pharmacological target for the treatment of neovascular ocular pathologies. S1P is a sphingolipid mediator that controls cellular growth, differentiation, survival and death. S1P actions are mediated by five G protein-coupled receptors (S1P1-5 receptors) which are abundantly expressed in all retinal and subretinal structures. The action of S1P on S1P1 receptors can reduce angiogenesis, increase endothelium integrity, reduce photoreceptor apoptosis and protect the retina against neurodegeneration. Conversely, S1P2 receptor signalling can increase neovascularisation, disrupt endothelial junctions, stimulate VEGF release, and induce retinal cell apoptosis and degeneration of neural retina. The aim of this review is to thoroughly discuss the role of S1P and its different receptor subtypes in angiogenesis, inflammation, apoptosis and fibrosis in order to determine which of these S1P-mediated processes may be targeted therapeutically.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationAlshaikh, R. A., Ryan, K. B. and Waeber, C. (2021) 'Sphingosine 1-phosphate, a potential target in neovascular retinal disease', British Journal of Ophthalmology. doi: 10.1136/bjophthalmol-2021-319115en
dc.identifier.doi10.1136/bjophthalmol-2021-319115en
dc.identifier.eissn1468-2079
dc.identifier.issn0007-1161
dc.identifier.journaltitleBritish Journal of Ophthalmologyen
dc.identifier.urihttps://hdl.handle.net/10468/11391
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.rights© 2021, the Authors. Published by BMJ Publishing Group Ltd. This article has been accepted for publication in British Journal of Ophthalmology following peer review, and the Version of Record can be accessed online at: http://dx.doi.org/10.1136/bjophthalmol-2021-319115 No commercial re-use.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectSphingosine-1 phosphateen
dc.subjectNeovascularizationen
dc.subjectVEGF blockersen
dc.subjectAngiogenesisen
dc.subjectAge-related macular degenerationen
dc.subjectDiabetic retinopathyen
dc.subjectRetinal vein occlusionen
dc.titleSphingosine 1-phosphate, a potential target in neovascular retinal diseaseen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Revised_Manuscript_with_figures.pdf
Size:
535.3 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles
Pharmacology and Therapeutics - Journal Articles